Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Executive Briefing - Biopartnering 2.0

This article was originally published in Scrip

Executive Summary

The biopharmaceutical industry's perennial search for innovation continues to drive diverse alliance activity between commercial partners of all stripes. More recently, the macroeconomic climate has been impacting on dealmaker behaviour, with the emergence of risk aversion, creative thinking and more emphasis on value in partners' decision making. Many firms are rethinking their relationships with leading universities as part of broader strategies to boost innovation. Expect biopartnering models to reach a new level, says Pete Chan.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts